The Food and Drug Administration (FDA) in the United States has approved the avelumab (Bavencio) plus axitinib (Inlyta) combination for first-line treatment of advanced renal cell carcinoma (RCC). The approval is the first by the FDA for an anti-PD-L1 therapy as part of a combination treatment for patients with advanced RCC. Around 20-30% of people […]
In this video interview, Professor Jens Bedke, Professor of Urology and Vice Chairman at the Department of Urology, University Hospital Tuebingen, Germany, discusses the advances in first-line treatment of renal cell carcinoma (RCC) from monotherapy, which has been the standard of care for the treatment of RCC, to combination therapies. First-line treatment with a combination […]
Results from a first-in-human phase 1 study of savolitinib in 48 patients with locally advanced or metastatic solid tumours was published in Clinical Cancer Research last month. Savolitinib is a selective MET inhibitor. In the study, the maximum tolerated dose was found to be 800 mg daily, and the recommended dose for phase 2 testing […]
A retrospective study recently reported in Journal for Immunotherapy of Cancer looked at the survival of renal cell carcinoma (RCC) patients who were assessed using the International Metastatic RCC Database Consortium (IMDC) for RCC risk and treated with high dose interleukin-2 (IL-2). These patients were entered on the PROCLAIMSM data base. The patients were followed […]
A recent case study, reported in Case Reports in Urology, presented an unusual case of a patient with metastatic renal cell carcinoma (RCC) and brain metastases who experienced a complete response to cabozantinib prior to radiation therapy. This case study contributes to the limited evidence on the activity of cabozantinib within the brain. The researchers […]
A real-world study recently reported in Journal for Immunotherapy of Cancer has shown a strong link between the occurrence of immune-related adverse events and survival in previously treated advanced or metastatic renal cell carcinoma (mRCC) patients treated with nivolumab. Immune-related adverse events were seen in 20% of patients. The median overall survival was not reached […]
A recent study, published in Cancer Science this month, suggests that PD-1 and PD-L1 expression by immune cells in kidney cancer tumours is involved in resistance to treatment, i.e. part of the reason why tumours stop responding to treatment. The researchers suggest that treatment with immune checkpoint inhibitors may be a promising therapeutic strategy for […]
A review in JAMA Oncology presents evidence to suggest that first-line immunotherapy combinations could improve efficacy among patients with advanced renal cell carcinoma (RCC). However, management of immune-related side effects is essential in maximising survival benefit and outcomes. Read more in Cure here
In the following interview, Dr Bradley McGregor, a medical oncologist specialising in genitourinary malignancies from the Dana-Farber Cancer Institute in Boston, USA, discusses the use of immunotherapy for genitourinary cancers in the elderly. Dr McGregor and his team looked at various checkpoint inhibitors in genitourinary cancer patients 65 years and older. They found that there […]
A recent study, published in the Journal of Cancer Research and Clinical Oncology this month, has investigated the effect of taking concomitant medication for renal cell carcinoma (RCC) in 388 patients who had surgery for localised kidney cancer. They also looked at various biomarkers for these concomitant medications. The researchers discovered that concomitant use of […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
